158 related articles for article (PubMed ID: 25997849)
21. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
22. Tear osmolarity, dry eye syndrome, blepharospasm and botulinum neurotoxin.
Girard B; de Saint Sauveur G
J Fr Ophtalmol; 2021 Dec; 44(10):1553-1559. PubMed ID: 34756743
[TBL] [Abstract][Full Text] [Related]
23. Systemic effect of local and small-dose botulinum toxin injection to unmask subclinical myasthenia gravis.
Iwase T; Iwase C
Graefes Arch Clin Exp Ophthalmol; 2006 Mar; 244(3):415-6. PubMed ID: 16175373
[No Abstract] [Full Text] [Related]
24. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
25. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox.
Dutton JJ; White JJ; Richard MJ
Ophthalmic Plast Reconstr Surg; 2006; 22(3):173-7. PubMed ID: 16714924
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type a and its uses in dry eye disease.
Victoria AC; Pino A
Plast Reconstr Surg; 2012 Jul; 130(1):209e-210e. PubMed ID: 22743932
[No Abstract] [Full Text] [Related]
27. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
Silveira-Moriyama L; Gonçalves LR; Chien HF; Barbosa ER
Arq Neuropsiquiatr; 2005 Jun; 63(2A):221-4. PubMed ID: 16100966
[TBL] [Abstract][Full Text] [Related]
28. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
[No Abstract] [Full Text] [Related]
29. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Streitová H; Bareš M
Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
[TBL] [Abstract][Full Text] [Related]
30. Apraxia of eyelid opening: clinical features and therapy.
Kerty E; Eidal K
Eur J Ophthalmol; 2006; 16(2):204-8. PubMed ID: 16703535
[TBL] [Abstract][Full Text] [Related]
31. Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients.
Grivet D; Robert PY; Thuret G; De Féligonde OP; Gain P; Maugery J; Adenis JP
Ophthalmic Plast Reconstr Surg; 2005 May; 21(3):230-4. PubMed ID: 15942501
[TBL] [Abstract][Full Text] [Related]
32. Protective Effect of Blepharospasm on the Anterior Segment of the Eye.
Biuk D; Vinković M; Barać J; Biuk E; Zelić Z; Matić S
Acta Clin Croat; 2018 Mar; 57(1):130-133. PubMed ID: 30256021
[TBL] [Abstract][Full Text] [Related]
33. Generalized botulism: diagnostic problems in a patient treated with botulinum toxin type A.
Fota-Markowska H; Mitosek-Szewczyk K; Hasiec T
Acta Ophthalmol Scand; 2007 Mar; 85(2):231-2. PubMed ID: 17305749
[No Abstract] [Full Text] [Related]
34. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.
Wabbels B; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):45-50. PubMed ID: 16874524
[TBL] [Abstract][Full Text] [Related]
36. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
Jankovic J; Comella C; Hanschmann A; Grafe S
Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
[TBL] [Abstract][Full Text] [Related]
38. Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.
Wabbels B; Fimmers R; Roggenkämper P
Toxins (Basel); 2022 Feb; 14(2):. PubMed ID: 35202148
[TBL] [Abstract][Full Text] [Related]
39. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Nallasamy N; Campos M
Br J Ophthalmol; 2016 Jul; 100(7):963-970. PubMed ID: 26541432
[TBL] [Abstract][Full Text] [Related]
40. Blepharospasm in a patient with pontine capillary telangiectasia.
Gilbert AL; Dillon WP; Horton JC
Ophthalmic Plast Reconstr Surg; 2012; 28(4):e92-3. PubMed ID: 22082598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
